These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1628372)

  • 1. Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion.
    Khayat D; Borel C; Azab M; Paraisot D; Malaurie E; Bouloux C; Weil M
    Cancer Chemother Pharmacol; 1992; 30(3):226-8. PubMed ID: 1628372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule.
    Kattan J; Durand M; Droz JP; Mahjoubi M; Marino JP; Azab M
    Am J Clin Oncol; 1994 Jun; 17(3):242-5. PubMed ID: 8192111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of N-methylformamide (NMF, NSC 3051).
    O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
    J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
    Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E
    Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
    Dodion P; Rozencweig M; Nicaise C; Piccart M; Cumps E; Crespeigne N; Kisner D; Kenis Y
    Eur J Cancer Clin Oncol; 1982 Jun; 18(6):519-22. PubMed ID: 6889528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
    Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
    J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
    Vogel CL; Gorowski E; Davila E; Eisenberger M; Kosinski J; Agarwal RP; Savaraj N
    Invest New Drugs; 1987; 5(2):187-98. PubMed ID: 3115912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
    Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
    Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
    Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG
    J Clin Oncol; 1991 Aug; 9(8):1487-94. PubMed ID: 2072148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.